Archer Aviation Inc vs Neurocrine Biosciences Inc — how do they compare? Archer Aviation Inc trades at $6.34 (market cap $5.23B), while Neurocrine Biosciences Inc trades at $156.6 (market cap $16.46B). The key difference: Neurocrine Biosciences Inc is far larger — about 3.1× Archer Aviation Inc's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Archer Aviation Inc nearer its low. Which is the better fit depends on your goals.
| ACHR | NBIX | |
|---|---|---|
Market Cap | $5.23B | $16.46B |
Sector | Industrials | Health |
52-Week High | $13.64 | $185.50 |
52-Week Low | $4.44 | $123.10 |
Enterprise Value | $3.79B | $16.48B |
Signals from Pluang's Aura AI — not financial advice
Archer Aviation (ACHR) trades at $6.30, up 0.64% today, with a bullish technical outlook from moving averages but overbought RSI signals. The company reported a Q2 2026 revenue beat but sustained heavy losses, with a net income margin of -11,589.86% in 2026. Recent news highlights a strategic deal with Boeing to acquire three businesses, broadening its defense and AI aviation portfolio, which fueled a significant stock rally.
The outlook remains speculative with high execution risks amid substantial cash burn, but analyst sentiment is strongly bullish (77.78% buy ratings) due to regulatory progress and Boeing's backing. Key risks include dilution from equity offerings, certification delays, and profitability challenges in the nascent eVTOL market.
Neurocrine Biosciences (NBIX) trades at $158.89, down 3.66% in the past 24 hours, reflecting near-term bearish technical signals. The stock shows strong fundamentals with Q2 2026 revenue growth of 39% year-over-year to $959 million and a net income margin of 20.91%. Recent news highlights include positive clinical data for INGREZZA and the initiation of a Phase 1 study for a GLP-1/GIP/glucagon receptor triple agonist, though safety concerns were raised for Vykat XR in Prader-Willi Syndrome.
The outlook remains positive given robust earnings beats, raised 2026 sales guidance, and a consensus price target of $208.82 implying significant upside. Risks include clinical trial setbacks, competitive pressures, and regulatory scrutiny. Analyst sentiment is strongly bullish with 86% buy ratings, supporting a growth-oriented investment case amid near-term volatility.
Trailing returns across standard periods
Latest headlines on both assets
Archer Aviation develops electric vertical takeoff and landing (eVTOL) aircraft for urban air mobility. Its flagship, Midnight aircraft, is designed for air taxi services, aiming to transform urban travel with sustainable aviation.
Read more on ACHR →Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →